Identification of CXCL9 chemokine as a potential biomarker for assessing clinical severity in COVID-19 patients

Authors

  • Nargiz Ibadullaeva Scientific department, Reference Laboratory, Administration, Research Institute of Virology, Tashkent, Uzbekistan https://orcid.org/0000-0001-8334-2548
  • Aziza Khikmatullaeva Scientific department, Reference Laboratory, Administration, Research Institute of Virology, Tashkent, Uzbekistan
  • Ulugbek Mirzaev Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan https://orcid.org/0000-0002-2986-5660
  • Nataliya Kan Scientific department, Reference Laboratory, Administration, Research Institute of Virology, Tashkent, Uzbekistan
  • Marina Bobkova Scientific department, Reference Laboratory, Administration, Research Institute of Virology, Tashkent, Uzbekistan https://orcid.org/0000-0001-5481-8957
  • Erkin Musabaev Scientific department, Reference Laboratory, Administration, Research Institute of Virology, Tashkent, Uzbekistan

DOI:

https://doi.org/10.3855/jidc.18537

Keywords:

COVID-19, IP-10, CXCL9, CCL17, IL28B

Abstract

Introduction: The severity and clinical outcome of COVID-19 depend on virus-specific factors and the host's inflammatory response. Identifying biomarkers of severe COVID-19 is a crucial condition and predicts disease severity.

Methodology: This study enrolled a total of 167 patients with COVID-19. These patients were categorized into three groups based on the severity of the disease: moderate course - 78 individuals, severe course - 52 individuals, and extremely severe course - 37 individuals. We analyzed chemokines (IP-10, CXCL9, CCL17) and cytokine IL28B levels using the enzyme immunoassay (EIA) method.

Results: CXCL9 levels were increased in severe and extremely severe cases compared to moderate ones. The CCL17 chemokine demonstrated significant elevation in severe cases. However, there was no significant difference in the level of IP-10, and IL28B in the compared groups.

Conclusions: Our findings suggest that CXCL9 and CCL17 chemokines could be used as biomarkers to assess the clinical status of patients with COVID-19 and can relate to disease severity. These biomarkers could aid in identifying patients at high risk for severe disease and help guide clinical decision-making for the effective management of COVID-19.

Author Biographies

Aziza Khikmatullaeva, Scientific department, Reference Laboratory, Administration, Research Institute of Virology, Tashkent, Uzbekistan

Scientific department

Ulugbek Mirzaev, Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan

Department of Epidemiology, Infectious Disease Control and Prevention

Nataliya Kan, Scientific department, Reference Laboratory, Administration, Research Institute of Virology, Tashkent, Uzbekistan

Reference laboratory

Marina Bobkova, Scientific department, Reference Laboratory, Administration, Research Institute of Virology, Tashkent, Uzbekistan

Scientific department

Erkin Musabaev, Scientific department, Reference Laboratory, Administration, Research Institute of Virology, Tashkent, Uzbekistan

Administration

Downloads

Published

2024-05-30

How to Cite

1.
Ibadullaeva N, Khikmatullaeva A, Mirzaev U, Kan N, Bobkova M, Musabaev E (2024) Identification of CXCL9 chemokine as a potential biomarker for assessing clinical severity in COVID-19 patients. J Infect Dev Ctries 18:672–678. doi: 10.3855/jidc.18537

Issue

Vol. 18 No. 05: May 2024

Section

Coronavirus Pandemic

License

Copyright (c) 2024 Nargiz Ibadullaeva, Aziza Khikmatullaeva, Ulugbek Mirzaev, Nataliya Kan, Marina Bobkova, Erkin Musabaev

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
Crossref
Scopus
Google Scholar
Europe PMC